James D Mancuso1, Roque Miramontes2, Carla A Winston2, C Robert Horsburgh3,4,5,6, Andrew N Hill2. 1. Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland. 2. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia; and. 3. Department of Epidemiology. 4. Department of Biostatistics, and. 5. Department of Global Health, School of Public Health, and. 6. Department of Medicine, School of Medicine, Boston University Boston, Massachusetts.
Abstract
Rationale: A central strategy of tuberculosis (TB) control in the United States is reducing the burden of latent TB infection (LTBI) through targeted testing and treatment of persons with untreated LTBI. Objectives: The objective of the study was to provide estimates of and risk factors for engagement in LTBI care in the overall U.S. population and among specific risk groups. Methods: We used nationally representative data from 7,080 participants in the 2011-2012 National Health and Nutrition Examination Survey. Engagement in LTBI care was assessed by estimating the proportion with a history of testing, diagnosis, treatment initiation, and treatment completion. Weighted methods were used to account for the complex survey design and to derive national estimates. Results: Only 1.4 million (10%) of an estimated 14.0 million individuals with an LTBI had previously completed treatment. Of the 12.6 million who did not complete LTBI treatment, 3.7 million (29%) had never been tested and 7.2 million (57%) received testing but had no history of diagnosis. High-risk groups showed low levels of engagement, including contacts of individuals with TB and persons born outside the United States. Conclusions: There is a reservoir of more than 12 million individuals in the United States who may be at risk for progression to TB disease and potential transmission. TB control programs and community providers should consider focused efforts to increase testing, diagnosis, and treatment for LTBI.
Rationale: A central strategy of tuberculosis (TB) control in the United States is reducing the burden of latent TB infection (LTBI) through targeted testing and treatment of persons with untreated LTBI. Objectives: The objective of the study was to provide estimates of and risk factors for engagement in LTBI care in the overall U.S. population and among specific risk groups. Methods: We used nationally representative data from 7,080 participants in the 2011-2012 National Health and Nutrition Examination Survey. Engagement in LTBI care was assessed by estimating the proportion with a history of testing, diagnosis, treatment initiation, and treatment completion. Weighted methods were used to account for the complex survey design and to derive national estimates. Results: Only 1.4 million (10%) of an estimated 14.0 million individuals with an LTBI had previously completed treatment. Of the 12.6 million who did not complete LTBI treatment, 3.7 million (29%) had never been tested and 7.2 million (57%) received testing but had no history of diagnosis. High-risk groups showed low levels of engagement, including contacts of individuals with TB and persons born outside the United States. Conclusions: There is a reservoir of more than 12 million individuals in the United States who may be at risk for progression to TB disease and potential transmission. TB control programs and community providers should consider focused efforts to increase testing, diagnosis, and treatment for LTBI.
Entities:
Keywords:
National Health and Nutrition Examination Survey; engagement in care; latent tuberculosis infection; tuberculosis epidemiology
Authors: Kai H Young; Melissa Ehman; Randall Reves; Brandy L Peterson Maddox; Awal Khan; Terence L Chorba; John Jereb Journal: MMWR Morb Mortal Wkly Rep Date: 2016-01-01 Impact factor: 17.586
Authors: James D Mancuso; Jeffrey M Diffenderfer; Bijan J Ghassemieh; David J Horne; Tzu-Cheg Kao Journal: Am J Respir Crit Care Med Date: 2016-08-15 Impact factor: 21.405
Authors: David M Lewinsohn; Michael K Leonard; Philip A LoBue; David L Cohn; Charles L Daley; Ed Desmond; Joseph Keane; Deborah A Lewinsohn; Ann M Loeffler; Gerald H Mazurek; Richard J O'Brien; Madhukar Pai; Luca Richeldi; Max Salfinger; Thomas M Shinnick; Timothy R Sterling; David M Warshauer; Gail L Woods Journal: Clin Infect Dis Date: 2016-12-08 Impact factor: 9.079
Authors: P W Colson; Y Hirsch-Moverman; J Bethel; P Vempaty; K Salcedo; K Wall; W Miranda; S Collins; C R Horsburgh Journal: Int J Tuberc Lung Dis Date: 2013-04 Impact factor: 2.373
Authors: Neela D Goswami; Lara Beth Gadkowski; Carla Piedrahita; Deborah Bissette; Marshall Alex Ahearn; Michela L M Blain; Truls Østbye; Jussi Saukkonen; Jason E Stout Journal: BMC Public Health Date: 2012-06-21 Impact factor: 3.295
Authors: Christopher Pease; Alice Zwerling; Ranjeeta Mallick; Mike Patterson; Patricia Demaio; Sandy Finn; Jean Allen; Deborah Van Dyk; Gonzalo G Alvarez Journal: BMC Infect Dis Date: 2019-10-24 Impact factor: 3.090